Trial reportThe British journal of ophthalmology2025
Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine.
Trial report in The British journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Defocus Incorporated Multiple Segments (DIMS) spectacle lenses versus 0.01% atropine for myopia control: a randomised trial in children from Central Europe.BMJ open ophthalmology · 2025Trial
- Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine.The British journal of ophthalmology · 2025Trial
- Adjunctive 0.05% Atropine for Children with Continued Rapid Myopia Progression During Defocus Incorporated Multiple Segments Spectacle Lens Treatment: A Retrospective Matched Cohort Study.Ophthalmology and therapy · 2026Article
- [Topical atropine for myopia prevention : Current study situation].Die Ophthalmologie · 2026Review
- Reduced myopia progression with low-dose atropine in DIMS non-responders and evidence of altered pupillary light reflex kinetics.Scientific reports · 2026Article
- Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control-A Narrative Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- Neuro-ophthalmic review on pediatric myopia: Advancing from refraction to a brain-centric model of axial growth.World journal of clinical pediatrics · 2026Review
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Current and Emerging Strategies for Myopia Control in Children: A Comprehensive Evidence-Based Review.Journal of clinical medicine · 2026Review
- Interventional modalities for the prevention and management of childhood myopia in frontiers in ophthalmology: PREC strategy for myopia in children.Frontiers in ophthalmology · 2026Article
- Influence of Astigmatism Type on Myopia Progression Among Children Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Management of myopia: a mini-review.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Effect of orthokeratology lens wear on axial length elongation in myopic children.Frontiers in medicine · 2026Article
- Article
- The Myopic Control Effect of Defocus Incorporated Multiple Segments' Spectacle Lens With Atropine in High Myopia Population.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia.
methodsRandomised controlled trial conducted on children aged 4-16 years with myopia between -1.00D and -6.00D and astigmatism ≤2.00D. Children were randomly allocated into two groups: 0.025% atropine and SV spectacle lenses treatment group (group A), and 0.025% atropine and DIMS spectacle lenses treatment group (group B). Cycloplegic spherical equivalent refraction (SER) and axial length were measured at baseline, 6 and 12 months.
results102 patients completed the 12-month follow-up: n=49 in group A, mean age 9.50±2.78 years and n=53 in group B, mean age 9.90±2.47 years. At 12 months, the mean AL±SD change was 0.18±0.16 mm in group A and 0.07±0.16 mm in group B (mean difference: 0.11, 95% CI: 0.05 to 0.17; p≤0.001). Mean SER±SD progression at 12 months was -0.19±0.42D and -0.09±0.35D in groups A and B, respectively (p=0.13). 39.6% of children in group B had no axial elongation over 12 months compared with 12.2% of the children in group A (p=0.002).
conclusionsCombination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses. Although not significant, SER differences between groups were lower in group B. These findings support a potential additive effect of the two treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.